- Function
- Main Sponsor
Main Sponsor
Website: illumina.com
Our mission is to improve human health by unlocking the power of the genome.
As a genomics pioneer, we have proven through focused and continued innovation how unlocking the power of the genome can exponentially improve the human condition and the world around us.
Our ability to drive patient outcomes has made us a trusted partner in health care. Today, we’re providing tools that enable the next generation of researchers and clinicians to usher in the future of personalized medicine.
Benefits of next-generation sequencing in oncology
As genomics-focused pharmacology begins to play a greater role in cancer treatment, next-generation sequencing (NGS) has emerged as a valuable method for obtaining a deeper and more accurate look into the molecular underpinnings of individual tumors.
Because NGS can assess multiple genes in a single assay, it eliminates the need to order multiple tests to identify the causative mutation.
What Is Comprehensive Genomic Profiling?
Comprehensive genomic profiling (CGP) is a next-generation sequencing (NGS) approach that uses a single assay to assess hundreds of genes including relevant cancer biomarkers, as established in guidelines and clinical trials, for therapy guidance.
Key benefits of CGP:
- Detect Multiple Biomarkers in a Single Assay. CGP can detect single nucleotide variants, indels, copy number variants, fusions, and splice variants) and genomic signatures such as TMB and MSI (tumor mutational burden and microsatellite instability, respectively), maximizing the ability to find clinically actionable alterations.
- Consolidate Testing to Save Time and Precious Samples. CGP consolidates biomarker detection into a single multiplex assay, eliminating the need for sequential testing. With a single test, you can assess the most prevalent as well as rare biomarkers.
- Identify Actionable Alterations. CGP can offer both actionable and potentially actionable results to help identify more effective therapeutic paths and innovative clinical trial options for cancer patients.
Learn more about CGP, visit: https://emea.illumina.com/destination/Defining-CGP.html
Medical Information about Illumina Products
Are you a health care provider with a medical question concerning an Illumina product?
Contact us using the form at the link below to receive evidence-based medical information: https://www.illumina.com/clinical/medical-information-resources.html
Medical Education/Research Grants & Sponsorships
Illumina offers grants and sponsorships to support research that aligns with our mission to unlock the power of the genome and drive the progress of genomics. We offer this support through medical education grants, medical research grants, investigator-sponsored research grants, collaborative research support, and medical sponsorships.
For complete details, visit https://emea.illumina.com/clinical/medical-information-resources/grants-sponsorships.html
Educational videos
Introduction to Homologous Recombination Deficiency (HRD) assessment
This educational video explores main concepts of homologous recombination deficiency (HRD) and different testing approaches. HRD is a mutational signature utilized in the field of precision Oncology, frequently with ovarian, breast, prostate, and pancreatic tumors.
Hear from oncology experts:
Does finding a rare mutation accomplish anything?
Rachel E. Sanborn, MD, presents the journey of a patient diagnosed with atypical carcinoid with brain metastases who benefited from the detection of a RET fusion by comprehensive genomic profiling.
Rachel E. Sanborn, MD is the medical director of the Thoracic Oncology and Phase I Clinical Trials Programs at the Earle A. Chiles Research Institute at Providence Cancer Institute.
Homologous Recombination Deficiency (HRD) testing in ovarian cancer
Isabelle Ray-Coquard, MD, PhD, explains how comprehensive genomic profiling (CGP) simultaneously provides HRD and BRCA status in ovarian cancer patients. She presents the case of a patient who benefited from CGP testing for these biomarkers and discusses how CGP can detect other actionable mutations.
Dr. Ray-Coquard is a medical oncologist at the Centre Léon Bérard, France, professor of medicine at the Université Claude Bernard Lyon, and president of the Gineco Group.
Testing for NTRK fusions
Vivek Subbiah, MD, explains how patients with rare and common tumors can benefit from next-generation-sequencing-based testing for NTRK gene fusions. He presents the case of a patient who benefited from precision medicine based on the detection of an NTRK1 fusion by comprehensive genomic profiling.
Dr. Subbiah is the chief of Early-Phase Drug Development at Sarah Cannon Research Institute.
Clinical utility of ctDNA testing
Atocha Romero, PharmD, PhD, explains the value of liquid biopsy-based comprehensive genomic profiling. Dr. Romero provides an overview of the results of the NADIM II clinical trials and discusses ctDNA testing to monitor disease and guide treatment.
Dr. Romero is the director of the Liquid Biopsy Laboratory of the Medical Oncology Department at the Hospital Universitario Puerta de Hierro in Madrid, Spain.
Liquid biopsy NGS in cancer care
Pashtoon Kasi, MD, MS, explains how liquid biopsy next-generation-sequencing (NGS)-based testing can benefit cancer patients. Dr. Kasi presents four colorectal cancer patient cases for whom comprehensive genomic profiling was done via liquid biopsy and results for clinically -relevant biomarkers were obtained in seven to eight days.
Dr. Kasi is the director of Colon Cancer Research and director of Precision Medicine Research for Liquid Biopsies at Weill Cornell Medicine.
Follow us:
ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.